Abstract 32P
Background
Hypoxia is characterized by low oxygen levels in tissues and plays a significant role in the development and progression of gliomas. Hypoxia induces activation of several signals including STAT3 which has been implicated in the cancer progression and development of drug resistance including in gliomas used temozolomide (TMZ) via modulation of O6-methylguanin-DNA-methyltransferase (MGMT) mediated repair of TMZ-induced DNA damage.
Methods
Our study was focused on the expression of STAT3 and hypoxia related factors in a set of repeatedly resected glioma patients (one patient without treatment, seven patients with chemoradiotherapy) and glioma cell lines with normal and knockout STAT3 using IHC, mutational and RT-PCR analyses correlated with clinical data.
Results
In patients' samples, IHC analysis showed that in all but one repeated glioma resections from individual patients pSTAT3 levels were elevated. Higher pSTAT3 levels as well as MGMT methylation status corresponded with a shortened survival of these patients. Further analyses carried out in cryopreserved glioma samples revealed upregulation of STAT3 in an untreated patient corresponding with upregulation of hypoxia factors (HIF1α, HIF1β), proangiogenic factor VEGFA and EGFR. STAT3 knockout in glioma cells produced a similar trend - downregulation of hypoxia and proangiogenic factors.
Conclusions
Our results demonstrated a biological relationship between the expression of pSTAT3, hypoxia and proangiogenic factors and MGMT methylation in both cultivated glioma cells and glioma resected samples. Moreover, we discovered that pSTAT3 levels tend to increase in repeated resections. MGMT methylation status and increased pSTAT3 levels in these samples correlate with shorter survival of investiagted glioma bearing patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This study was supported by Ministry of Health, Czech Republic, project No. NU20-03-00360.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract
177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress
Presenter: Hans Raskov
Session: Cocktail & Poster Display session
Resources:
Abstract